Premium
Frontispiece: Bioorthogonal Uncaging of the Active Metabolite of Irinotecan by Palladium‐Functionalized Microdevices
Author(s) -
Adam Catherine,
PérezLópez Ana M.,
Hamilton Lloyd,
RubioRuiz Belén,
Bray Thomas L.,
Sieger Dirk,
Brennan Paul M.,
UncitiBroceta Asier
Publication year - 2018
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201886364
Subject(s) - bioorthogonal chemistry , prodrug , irinotecan , active metabolite , metabolite , chemistry , combinatorial chemistry , pharmacology , medicine , biochemistry , cancer , click chemistry , colorectal cancer
Systemic side effects limit the efficacy of chemotherapy regimens. To reduce toxicity, a metabolically stable prodrug of SN‐38 (irinotecan's active metabolite) has been designed to be exclusively activated by Pd‐functionalized microdevices that can be implanted into tumors. It is also shown the first concomitant uncaging of two drugs used in clinical combinations by the same bioorthogonal method. More information can be found in the Full Paper by P. M. Brennan, A. Unciti‐Broceta, et al. on page 16783 ff.